Patent US4575847A successfully refreshed from Google Patents.
Patent US4044462A successfully refreshed from Google Patents.
Patent US5571801A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5571801A Expired / Lapsed US ⏱️ 0.0 years remaining

Plasma expander and blood substitute

Assignee: Lineage Cell Therapeutics Inc
•
Filing: 1995-05-22
•
Granted: 1996-11-05
•
Expires: 2015-05-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed. The use of the plasma-like solution in organ transplant, novel chemotherapy procedures, and tissue, organ and organism cryopreservation are also disclosed.

Inventors

  • 👤 Paul E. Segall
  • 👤 Harold D. Waitz
  • 👤 Hal Sternberg
  • 👤 Judith M. Segall

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 22:51
CPC Classifications
A; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/125; A01N1/16; A01N1/162; A61; A61K; A61K33/00; A61K33/06; A61K33/10; A61K33/14; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61P; A61P7/00; A61P7/08

Claims Analysis

Total Claims: 33
Claim 1
Independent Claim 93 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble oncotic agents, one of which is a water soluble polysaccharide oncotic agent and one of which is serum albumin, wherein said polysaccharide is selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
Claim 2
Dependent Claim 93 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble oncotic agents, one of which is a water soluble polysaccharide oncotic agent and one of which is serum albumin, wherein said polysaccharide is selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
Claim 3
Dependent Claim 30 words
The plasma expander and blood substitute of claim 1 wherein the ratio of the weight of said water soluble polysaccharide oncotic agent to serum albumin is between 1:1 and 1:2.
Claim 4
Dependent Claim 40 words
The plasma expander and blood substitute of claim 1 wherein the combined percentage of said water soluble polysaccharide oncotic agent and serum albumin in a solution of said plasma expander and blood substitute is in a range between 4%-6% (w/v).
Claim 5
Dependent Claim 40 words
The plasma expander and blood substitute of claim 1 further comprising catios in the following concentrations: Na + 110 to 120 mEq/l, Ca ++ about 5 mEq/l, K + 0 to 3 mEq/l, and Mg ++ 0 to 0.9 mEq/l.
Claim 6
Dependent Claim 18 words
The plasma expander and blood substitute of claim 4 wherein said cations are supplied as dissolved chloride salts.
Claim 7
Dependent Claim 40 words
The plasma expander and blood substitute of claim 1 further comprising cations in the following concentrations: Na + 110 to 120 mEq/l, Ca ++ about 5 mEq/l, K + 4 to 5 mEq/l, and Mg ++ 1 to 3 meq/l.
Claim 8
Dependent Claim 18 words
The plasma expander and blood substitute of claim 6 wherein said cations are supplied as dissolved chloride salts.
Claim 9
Dependent Claim 15 words
The plasma expander and blood substitute of claim 1 further comprising at least one buffer.
Claim 10
Dependent Claim 16 words
The plasma expander and blood substitute of claim 8 wherein said buffer is lactate and bicarbonate.
Claim 11
Dependent Claim 14 words
The plasma expander and blood substitute of claim 8 wherein said buffer is lactate.
Claim 12
Dependent Claim 14 words
The plasma expander and blood substitute of claim 8 wherein said buffer is bicarbonate.
Claim 13
Dependent Claim 29 words
The plasma expander and blood substitute of claim 8, wherein said buffer is a biological buffer having a buffering capacity in the pH range of about 7.2 to 7.8.
Claim 14
Dependent Claim 21 words
The plasma expander and blood substitute of claim 1 further comprising aqueous vitamin K in a concentration of about 1-4 mg/l.
Claim 15
Dependent Claim 12 words
The plasma expander and blood substitute of claim 1 further comprising amylase.
Claim 16
Dependent Claim 17 words
The plasma expander and blood substitute of claim 1 further comprising at least one cold protecting agent.
Claim 17
Dependent Claim 41 words
The plasma expander and blood substitute of claim 15 wherein said cold protecting agent is at least one member selected from the group consisting of glycerol, propylene glycol, ethylene glycol, DMSO, urea, TMA, TMAO, formamide, propanediol, glucose, sucrose, sorbitol, and trehalose.
Claim 18
Dependent Claim 27 words
The plasma expander and blood substitute of claim 15 wherein said cold protecting agent is comprised of about 4% DMSO, about 4% glycerol and about 0.05M glucose.
Claim 19
Dependent Claim 159 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof comprising a single solution with at least two water soluble oncotic agents, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and wherein one of said oncotic agents is a water soluble polysaccharide selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, and one of which is serum albumin, wherein the ratio of the weight of said water soluble polysaccharide to said serum albumin is between 1:1 and 1:2, and further comprising cations in the following concentrations: Na + 110-120 mEq/l, Ca ++ about 5 mEq/l, K + 0 to 5 mEq/l, and Mg ++ 0.9 to 1.5 mEq/l, and at least one buffer, said plasma expander and blood substitute having a pH between 5 and 6.8.
Claim 20
Dependent Claim 159 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof comprising a single solution with at least two water soluble oncotic agents, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and wherein one of said oncotic agents is a water soluble polysaccharide selected from the group consisting of dextran 70 and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, and one of which is serum albumin, wherein the ratio of the weight of said water soluble polysaccharide to said serum albumin is between 1:1 and 1:2, and further comprising cations in the following concentrations: Na + 110-120 mEq/l, Ca ++ about 5 mEq/l, K + 0 to 5 mEq/l, and Mg ++ 0.9 to 1.5 mEq/l, and at least one buffer, said plasma expander and blood substitute having a pH between 5 and 6.8.
Claim 21
Dependent Claim 14 words
The plasma expander and blood substitute of claim 18 wherein said buffer is lactate.
Claim 22
Dependent Claim 14 words
The plasma expander and blood substitute of claim 18 wherein said buffer is bicarbonate.
Claim 23
Dependent Claim 16 words
The plasma expander and blood substitute of claim 18 wherein said buffer is lactate and bicarbonate.
Claim 24
Dependent Claim 21 words
The plasma expander and blood substitute of claim 18 further comprising aqueous vitamin K in a concentration of about 1-4 mg/l.
Claim 25
Dependent Claim 12 words
The plasma expander and blood substitute of claim 18 further comprising amylase.
Claim 26
Dependent Claim 29 words
The plasma expander and blood substitute of claim 18, wherein said buffer is a biological buffer having a buffering capacity in the pH range of about 7.2 to 7.8.
Claim 27
Dependent Claim 96 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and further comprising at least one cold protecting agent.
Claim 28
Dependent Claim 96 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent, and further comprising at least one cold protecting agent.
Claim 29
Dependent Claim 41 words
The plasma expander and blood substitute of claim 25 wherein said cold protecting agent is at least one member selected from the group consisting of glycerol, propylene glycol, ethylene glycol, DMSO, urea, TMA, TMAO, formamide, propanediol, glucose, sucrose, sorbitol and trehalose.
Claim 30
Dependent Claim 27 words
The plasma expander and blood substitute of claim 25 wherein said cold protecting agent is comprised of about 4% DMSO, about 4% glycerol and about 0.05M glucose.
Claim 31
Dependent Claim 87 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
Claim 32
Dependent Claim 87 words
A blood-free plasma expander and blood substitute for use in a subject in need thereof, comprising a single solution with at least two water soluble polysaccharide oncotic agents selected from the group consisting of dextran 40, dextran 70, hydroxyethyl starch having an average molecular weight of 350,000 daltons or lower, and hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, wherein one of said oncotic agents is eliminated from the circulation of said subject at a relatively greater rate than the other oncotic agent.
Claim 33
Dependent Claim 30 words
The blood-free plasma expander and blood substitute of claim 28, wherein said oncotic agents are hydroxyethyl starch having an average molecular weight of 400,000 daltons or higher, and dextran 40.

References Cited (Backward Citations)

US3758382A Cited
US4923442A Cited
US5130230A Cited
USRE34077E Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-11-05 2000-05-06 2000-11-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-11-05 2004-05-06 2004-11-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-11-05 2008-05-06 2008-11-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag